Morgan Stanley raises Kangfang Bio's target price by 22% to HKD 78 and reiterates its buy rating.

On September 16th, Jinshi data reported that Morgan Stanley published a research report, according to the recent positive data published by Kangfang Biotechnology (09926.HK) at the WCLC conference, which clearly predicted the potential contribution of ivonescimab to the overseas market. Morgan Stanley predicts that the group’s losses in the next two years will narrow by 31% and 17% respectively; the profit forecast for 2026 will rise by 13%, and the profit forecast for 2027-2030 will also increase by 4-19%. At the same time, Morgan Stanley raised the target price of Kangfang Biotechnology by 22% to HKD 78, and reiterated the buy rating. The report stated that Morgan Stanley adjusted its estimated full-year revenue and cost for 2024 based on the performance trend of Kangfang Biotechnology in the first half of this year, assuming a downward trend in the full-year operating expense ratio for 2024, with the R&D ratio decreased from 65% to 58% and the sales ratio decreased from 60% to 55%.